Quarterly report [Sections 13 or 15(d)]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - LadRx (Details)

v3.25.1
Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - LadRx (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 21, 2023
Jun. 30, 2024
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Agreements          
Contingent consideration under RPAs, AAAs, and CPPAs         $ 3,000
Payments of consideration under RPAs, AAAs and CPPAs     $ 8,000 $ 15,000  
Long-term royalty and commercial payment receivables under the cost recovery method     59,916   55,936
Receipts under RPAs, AAAs, and CPPAs     1,307 $ 7,771  
Short-term royalty and commercial payment receivables under the cost recovery method     413   413
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement          
Agreements          
Amount of regulatory milestone payment removed   $ 4,000      
Payments of consideration under RPAs, AAAs and CPPAs $ 5,000        
Maximum regulatory and commercial sales milestone payments 6,000        
Maximum regulatory milestone payments 5,000        
Maximum commercial sales milestone payments 1,000        
Long-term royalty and commercial payment receivables under the cost recovery method 6,000        
Receipts under RPAs, AAAs, and CPPAs     400    
Short-term royalty and commercial payment receivables under the cost recovery method     400    
Allowance for credit losses     $ 0   0
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones          
Agreements          
Contingent consideration under RPAs, AAAs, and CPPAs $ 1,000        
Payments of consideration under RPAs, AAAs and CPPAs         1,000
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Sales-based milestones          
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs         $ 1,000
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Aldoxorubicin | Regulatory milestones          
Agreements          
Contingent consideration under RPAs, AAAs, and CPPAs   $ 0